Human hepatocytes have been observed to contain GLP-1 receptors, and there is a hypothesis suggesting that activating these receptors with GLP-1 receptor agonists may yield beneficial outcomes on hepatic steatosis, fatty acid oxidation, lipotoxicity, and the cytokines linked to liver inflammation and fibrosis [104]. This evidence concerns the gene GLP1R and inflammatory response.